SCLAFANI, Francesco, Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE, Elizabeth SMYTH, Mark PEETERS, Radka OBERMANNOVÁ, Cindy NEUZILLET, Manfred P LUTZ, Thibaud KOESSLER, Irit BEN-AHARON, Dirk ARNOLD, Maria ALSINA a Markus MOEHLER. Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group. CLINICAL COLORECTAL CANCER. DALLAS: CIG MEDIA GROUP, LP, 2022, roč. 21, č. 3, s. 188-197. ISSN 1533-0028. Dostupné z: https://dx.doi.org/10.1016/j.clcc.2022.04.001.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group
Autoři SCLAFANI, Francesco (garant), Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE, Elizabeth SMYTH, Mark PEETERS, Radka OBERMANNOVÁ (203 Česká republika, domácí), Cindy NEUZILLET, Manfred P LUTZ, Thibaud KOESSLER, Irit BEN-AHARON, Dirk ARNOLD, Maria ALSINA a Markus MOEHLER.
Vydání CLINICAL COLORECTAL CANCER, DALLAS, CIG MEDIA GROUP, LP, 2022, 1533-0028.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.400
Kód RIV RIV/00216224:14110/22:00128356
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.clcc.2022.04.001
UT WoS 000898614900008
Klíčová slova anglicky Clinical trials; Meeting; Esophago-gastric cancers; Hepato-pancreatico-biliary cancers; Colorectal cancers
Štítky 14110516, 14110811, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 30. 1. 2023 12:51.
Anotace
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.
VytisknoutZobrazeno: 18. 7. 2024 15:25